作者
Eric J Lenze, Caline Mattar, Charles F Zorumski, Angela Stevens, Julie Schweiger, Ginger E Nicol, J Philip Miller, Lei Yang, Michael Yingling, Michael S Avidan, Angela M Reiersen
发表日期
2020/12/8
期刊
Jama
卷号
324
期号
22
页码范围
2292-2300
出版商
American Medical Association
简介
Importance
Coronavirus disease 2019 (COVID-19) may lead to serious illness as a result of an excessive immune response. Fluvoxamine may prevent clinical deterioration by stimulating the σ-1 receptor, which regulates cytokine production.
Objective
To determine whether fluvoxamine, given during mild COVID-19 illness, prevents clinical deterioration and decreases the severity of disease.
Design, Setting, and Participants
Double-blind, randomized, fully remote (contactless) clinical trial of fluvoxamine vs placebo. Participants were community-living, nonhospitalized adults with confirmed severe acute respiratory syndrome coronavirus 2 infection, with COVID-19 symptom onset within 7 days and oxygen saturation of 92% or greater. One hundred fifty-two participants were enrolled from the St Louis metropolitan area (Missouri and Illinois) from April 10, 2020, to August 5, 2020. The final date of follow-up was …
学术搜索中的文章
EJ Lenze, C Mattar, CF Zorumski, A Stevens… - Jama, 2020